HCAT Stock Analysis: Buy, Sell, or Hold?
HCAT - Health Catalyst, Inc Common Stock
$1.72
-0.02 (-1.15%)
▼
5d:
-7.03%
30d:
+33.33%
90d:
+39.84%
HOLD
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When HCAT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HCAT trades at premium valuation expecting 30.3% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: HCAT trades at premium valuation expecting 30.3% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: HCAT is currently trading at $1.72, which is considered extended relative to its 30-day fair value range of $1.26 to $1.74. From a valuation perspective, the stock is trading at a premium (Forward PE: 18.6) compared to its historical average (8.4). At these levels, the market is pricing in 30.3% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, HCAT is in a strong downtrend. Immediate support is located at $1.24, while resistance sits at $2.23.
Market Sentiment: HCAT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HCAT is in a strong downtrend. Immediate support is located at $1.24, while resistance sits at $2.23.
Market Sentiment: HCAT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.26 -
$1.74
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
Protect Your Profits
Holding HCAT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($1.75)
- BEARISH: Market expects 30.3% growth - appears too optimistic based on history
- CAUTION: 5-day price weakness (-7.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.26 -
$1.74
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.24
Resistance Level
$2.23
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.63
Wall Street Target
$1.75
(+1.7%)
Revenue Growth (YoY)
-10.9%
Profit Margin
-87.7%
Valuation Premium vs History
+30.3% premium
PE vs Historical
18.6 vs 8.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+30.3%
(market-implied from PE analysis)
1-Year Target
$2.24
(+30%)
2-Year Target
$2.92
(+70%)
3-Year Target
$3.81
(+121%)
3-Yr Target (if PE normalizes)
(PE: 19→8)
PE COMPRESSION
$1.72
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 119.8%)
$6.78
(+295%)
Base:
(SPY PE: 18.6, Growth: 119.8%)
$5.80
(+238%)
Bear:
(PE: 8.4, Growth: 119.8%)
$2.62
(+52%)
Share & Embed Analysis
Last updated: June 23, 2026 6:33 AM ET
Data refreshes hourly during market hours. Next update: 7:33 AM
Data refreshes hourly during market hours. Next update: 7:33 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HCAT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Health Information Services Stocks
Top-rated stocks in Health Information Services by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VEEV
Veeva Systems Inc Class A |
BUY
32 analysts |
$245 | 54 HOLD |
|
PRVA
Privia Health Group Inc |
STRONG BUY
21 analysts |
$31 | 54 HOLD |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$90 | 57 HOLD |
|
PHR
Phreesia Inc |
STRONG BUY
15 analysts |
$14 | 55 HOLD |
|
WAY
Waystar Holding Corp. Co… |
STRONG BUY
13 analysts |
$34 | 55 HOLD |
Advanced HCAT Option Strategies
Professional options setups generated by AI based on today's HCAT price and gamma walls.
